Abstract��OBJECTIVE To explore the clinical regularities and risk factor of abnormal liver function associated with LMWH in pulmonary thromboembolism patients. METHODS Clinical date of pulmonary thromboembolism patients in use of LMWH was collected and analyzed from January 2008 to December 2016. RESULTS 97 cases were enrolled. Of them, there were 76 cases were assessed as probable or possible. Single factor analysis showed the the levels of Scr (P=0.000), ALT (P=0.000), AST (P=0.000), ��-GGT (P=0.000), ALP (P=0.023), co-infection (P=0.024) and Ccr (P=0.026) had statistically significant difference. Multivariate analysis indicated that co-infection (OR=1.982, P=0.022) and high level of Scr (OR=1.045, P=0.000) were the independent risk factors of abnormal liver function associated with LMWH in PTE. CONCLUSION The incidence of abnormal liver function due to LMWH in PTE patients is high. With high level of Scr and/or co-infection patients are high-risk persons of abnormal liver function. It is necessary to dynamically evaluate the liver function during hospitalization. Symptomatic treatment can be significant if the liver function become abnormal.
WANG J Y. Internal Medicine(�ڿ�ѧ)[M]. Second Edition. Beijing: People��s Medical Publishing House, 2013: 61-65.
[2]
HEIT J A. The epidemiology of venous thromboembolism in the community [J]. Arterioscler Thromb Vasc Biol, 2008, 28(3): 370-372.
[3]
ZHANG X, YU W C. Epidemiological and clinical features of pulmonary embolism [J]. Shandong Med J(ɽ��ҽҩ), 2010, 50(3): 106-107.
[4]
LIU C F. Effect of low molecular weight heparin with unfractionated heparin in the treatment of pulmonary embolism [J]. Cardiovascular Dis J Integ Tradit Chin West Med(����ҽ�����Ѫ�ܲ���־), 2014, 9(9): 13-14.
[5]
GU J, YANG J, ZHANG H Y, et al. Compare of molecule characteristics and bioactivity of low-molecular-weight-hepar in products in market [J]. Chin Pharm J(�й�ҩѧ��־), 2007, 42(6): 461-465.
[6]
WANG W, TONG B G. The application of low molecular heparin in cardiovascular disease [J]. Chin J Clin Pharm(�й��ٴ�ҩ��ѧ��־), 2000, 9(4): 263-266.
[7]
GAO Y J, CHEN S G. Clinical significance of detection of liver function and myocardial enzyme spectrum in children with rotavirus enteritis [J]. Pract Clin Med(ʵ���ٴ�ҽѧ), 2014,15(4): 80-82.
[8]
WANG F Q, ZHANG T M. Recent study of low-molecular-weight-hepar [J]. Chin Pharm J(�й�ҩѧ��־), 1993, 28(11): 646-649.
[9]
ZHOU H, CHEN S S. Low molecular weight heparin-induced hepatic dysfunction in 5 patients with pulmonary thromboembolism [J]. Adverese Drug React J(ҩ�ﲻ����Ӧ), 2010, 12(5): 346-348.
[10]
ERICA L B, THEODORE L, EDWARD S, et al. Probable enoxaparin-induced hepatotoxicity [J]. Am J Health Syst Pharm, 2009, 66(7): 638-641.
[11]
KATHERINE J H, SHANNON J M, JAMES H L. Enoxaparin-induced liver injury: case report and review of the literature and FDA adverse event reporting system (FAERS) [J]. Drug Saf-Case Rep, 2015, 2(17):10-17.
[12]
BJORNSSON E S, JONASSON J G. Drug - induced cholestasis [J]. Clin Liver Dis, 2013, 17(2): 191-209.
[13]
REUBEN A, KOCH D G, LEE W M. Drug-induced acute liver failure: results of a US multicenter, prospective study [J]. Hepatology, 2010, 52(6): 2065-2076.
[14]
WU D G, SONG Z M. The mechanism and clinical application of hepatocin [J]. Chin Foreign Women Health(���⸾������), 2011, 19(8): 271.
2017, Vol. 52 
